The European Medicines Agency has recommended the marketing authorization of RASONQUE™.
Revolution Medicines Inc has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its drug RASONQUE™ (daraxonrasib), aimed at treating metastatic pancreatic cancer. This recommendation could lead to marketing authorization in the European Union, marking a significant milestone for the company. The stock closed at US$191.71, reflecting a 2.70% increase on the day of the announcement.
Investor takeaway: Revolution Medicines' positive CHMP opinion may influence investor sentiment as the company seeks to expand its market presence.
Advertisement
Revolution Medicines Inc
RVMD.US
RVMD.US
Revolution Medicines Inc
WealthAwesomeMarket cap
$40.57B
52W high
$224.31
52W low
$52.48
1W change
+0.61%
Beta
1.40
Analyst Price Targets
Based on 24 analysts covering RVMD · as of Oct 16, 2026
Wall Street analysts forecast RVMD stock price to rise 36.9% over the next 12 months.
Consensus
Strong Buy4.71 / 5.00
Avg. Target
C$259.18
+36.9% Upside
Previously C$259.14 on Oct 12, 2026
Current Price
C$189.26
Last close
Analyst Breakdown (24 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RVMD's historical volatility
30-Day Vol
36.4%
Annualized
90-Day Vol
39.3%
Annualized
Trend (90d)
+14.1%
Annualized drift
90d Mean
C$199.00
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$192.45 | C$169.71 – C$218.24 |
| 60 trading days | C$195.70 | C$163.82 – C$233.79 |
| 90 trading days | C$199.00 | C$160.06 – C$247.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Revolution Medicines’ stock increased by 2.70% following the news.
The stock closed at US$191.71, with a trading volume of 590,115 shares, slightly above its 20-day average.
Bull case
The positive CHMP opinion could boost Revolution Medicines' market potential and support its cancer treatment pipeline.
Bear case
Despite the encouraging news, the company still faces challenges in achieving profitability, as indicated by its current financial metrics.
Positive CHMP Opinion for RASONQUE™
Advertisement
Revolution Medicines Inc announced that its investigational drug RASONQUE™ (daraxonrasib) has received a positive opinion from the CHMP, recommending its marketing authorization in the European Union for treating metastatic pancreatic cancer. This recommendation is a crucial step towards making the drug available in the EU market, potentially benefiting patients with this challenging condition. The news comes as the company positions itself in a competitive oncology landscape.
Market Reaction and Performance Metrics
Following the announcement, Revolution Medicines' stock rose by 2.70%, closing at US$191.71. The trading volume was 590,115 shares, which is 1.02 times the 20-day average volume of 2,412,034 shares. In terms of performance, the stock has experienced a decline of 5.65% over the past month but has increased by 144.90% year-to-date. The stock price is currently 5.8% below its 50-day moving average of US$203.56, while it is 28.2% above its 200-day moving average of US$149.48.
Future Developments to Monitor
Investors will be watching for the official marketing authorization from the European Medicines Agency, which could further impact the company's growth trajectory. The average analyst target for Revolution Medicines is US$259.14, suggesting an implied move of 35.2% from the last close. Additionally, ongoing clinical trials and the company's strategy to address its profitability challenges, reflected in a negative profit margin of 0.0% and a return on equity of -79.1%, will be key areas of focus as Revolution Medicines moves forward.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
